PEXA AB CLASS B
0.36
SEK
-0.04
(-10.50%)
PEXA AB CLASS B
NGM:PEXA.BTA.B
(Nordic Growth Market)
Recent
price
0.36
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- PExA AB (publ) is a Sweden-based medical technology company that develops, manufactures, and commercializes non-invasive sampling and diagnostic instrumentation for respiratory medicine and biomarker research. The company specializes in patented technology that collects microscopic particles from exhaled air, enabling direct and non-invasive sampling of respiratory tract lining fluid (RTLF) from the distal small airways of the human lung. PExA AB provides a portfolio of research products and analytical solutions, including the PExA 2.1 core sampling instrument; single-use sampling kits and particle collection consumables; software systems for tracking breathing maneuvers and real-time particle quantification; specialized accessories for sample preservation and transport; analytical and laboratory support services for biomarker discovery, lipidomics, and proteomics; and instrument rental programs for clinical trials. The company serves pharmaceutical manufacturers, contract research organizations (CROs), university hospitals, academic research institutes, and government health agencies conducting research in chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF), lung cancer, cystic fibrosis, and occupational lung diseases. In recent developments, PExA AB expanded its business strategy from providing research instrumentation to identifying and patenting proprietary diagnostic biomarkers, highlighted by patent applications covering protein biomarker patterns for early-stage lung cancer detection. The company also executed a multi-unit commercial rental agreement with a global pharmaceutical company to deploy PExA 2.1 instruments in international multicenter clinical studies for idiopathic pulmonary fibrosis and completed a regulatory-approved directed share issue to finance operational and commercial expansion. Founded in 2014 as a spin-out from the University of Gothenburg, PExA AB is headquartered in Gothenburg, Sweden, and operates internationally across Europe, North America, and other global research markets.